Additionally, more research is needed to explore how to reduce the antagonistic side effects caused by mTOR signal blockade, the impact of different PI3K inhibitors on the transport and differentiation of pathogenic T cells, and the downstream effectors of PI3K that may be involved in metabolic diseases. The gene discussed is MTOR; the disease is metabolic disease.